AKT1 and neoplasm: Moreover, LY294002 inhibition of the NF-κB pathway in tumor and non-tumor oral cells demonstrates PI3K/AKT1 participation, although, constitutively, active Akt promotes κB kinase inhibitor (IKK) activation [49].